NYSE:BAX - Baxter International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$74.32 +0.58 (+0.79 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$74.32
Today's Range$73.74 - $74.86
52-Week Range$58.81 - $75.62
Volume3.37 million shs
Average Volume3.06 million shs
Market Capitalization$39.49 billion
P/E Ratio29.97
Dividend Yield1.03%
Beta0.81
Baxter International logoBaxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

Receive BAX News and Ratings via Email

Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BAX
CUSIP07181310
Phone224-948-2000

Debt

Debt-to-Equity Ratio0.39
Current Ratio2.63
Quick Ratio2.03

Price-To-Earnings

Trailing P/E Ratio29.97
Forward P/E Ratio25.72
P/E Growth1.9

Sales & Book Value

Annual Sales$10.56 billion
Price / Sales3.77
Cash Flow$3.9532 per share
Price / Cash18.80
Book Value$16.73 per share
Price / Book4.44

Profitability

EPS (Most Recent Fiscal Year)$2.48
Net Income$717 million
Net Margins7.75%
Return on Equity15.70%
Return on Assets8.44%

Miscellaneous

Employees47,000
Outstanding Shares535,490,000

The Truth About Cryptocurrencies

Baxter International (NYSE:BAX) Frequently Asked Questions

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International declared a quarterly dividend on Tuesday, May 8th. Investors of record on Friday, June 1st will be given a dividend of $0.19 per share on Monday, July 2nd. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, May 31st. This is an increase from Baxter International's previous quarterly dividend of $0.16. View Baxter International's Dividend History.

How will Baxter International's stock buyback program work?

Baxter International announced that its Board of Directors has authorized a stock buyback plan on Wednesday, February 21st 2018, which authorizes the company to repurchase $1,500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.

How were Baxter International's earnings last quarter?

Baxter International Inc (NYSE:BAX) announced its quarterly earnings results on Thursday, April, 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.08. The medical instruments supplier earned $2.68 billion during the quarter, compared to analysts' expectations of $2.62 billion. Baxter International had a net margin of 7.75% and a return on equity of 15.70%. The company's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.58 EPS. View Baxter International's Earnings History.

When is Baxter International's next earnings date?

Baxter International is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Baxter International.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $2.85-2.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.78. The company issued revenue guidance of $11.3-11.4 billion, compared to the consensus revenue estimate of $11.25 billion.Baxter International also updated its Q2 guidance to $0.69-0.71 EPS.

What price target have analysts set for BAX?

16 analysts have issued twelve-month price targets for Baxter International's shares. Their predictions range from $62.00 to $83.00. On average, they anticipate Baxter International's stock price to reach $72.7333 in the next year. View Analyst Ratings for Baxter International.

Who are some of Baxter International's key competitors?

Who are Baxter International's key executives?

Baxter International's management team includes the folowing people:
  • Mr. José E. Almeida, Chairman, Pres & CEO (Age 56)
  • Mr. James K. Saccaro, Exec. VP & CFO (Age 45)
  • Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 55)
  • Mr. Brik V. Eyre, Sr. VP & Pres of Americas (Age 54)
  • Mr. Giuseppe Accogli, Sr. VP & Pres of Global Bus.es (Age 47)

Has Baxter International been receiving favorable news coverage?

News articles about BAX stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Baxter International earned a media sentiment score of 0.06 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 46.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Baxter International's major shareholders?

Baxter International's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.05%), Veritas Asset Management LLP (1.77%), Northern Trust Corp (1.65%), Wells Fargo & Company MN (1.07%), Old Mutual Global Investors UK Ltd. (0.65%) and Legal & General Group Plc (0.53%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.

Which institutional investors are selling Baxter International stock?

BAX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Prudential Financial Inc., American Century Companies Inc., Wells Fargo & Company MN, Aristotle Capital Management LLC, CI Global Investments Inc., Veritas Asset Management LLP and Northern Trust Corp. Company insiders that have sold Baxter International company stock in the last year include Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Insider Buying and Selling for Baxter International.

Which institutional investors are buying Baxter International stock?

BAX stock was purchased by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Point72 Asset Management L.P., The Manufacturers Life Insurance Company, Natixis, Old Mutual Global Investors UK Ltd., BNP Paribas Arbitrage SA, Mackay Shields LLC and Eaton Vance Management. View Insider Buying and Selling for Baxter International.

How do I buy shares of Baxter International?

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxter International's stock price today?

One share of BAX stock can currently be purchased for approximately $74.32.

How big of a company is Baxter International?

Baxter International has a market capitalization of $39.49 billion and generates $10.56 billion in revenue each year. The medical instruments supplier earns $717 million in net income (profit) each year or $2.48 on an earnings per share basis. Baxter International employs 47,000 workers across the globe.

How can I contact Baxter International?

Baxter International's mailing address is One Baxter Parkway, DEERFIELD IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]


MarketBeat Community Rating for Baxter International (BAX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  508 (Vote Outperform)
Underperform Votes:  446 (Vote Underperform)
Total Votes:  954
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe BAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.